Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omburtamab I-131 - Memorial Sloan Kettering Cancer

Next Previous
Drug Profile

Omburtamab I-131 - Memorial Sloan Kettering Cancer

Alternative Names: 131 I-8H9; 8H9-I-131; Burtomab I-131; Iodine I 131 labelled monoclonal antibody 8H9; Iodine I 131 MOAB 8H9; Monoclonal-antibody-8H9-I-131; OMBLASTYS

Latest Information Update: 21 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; Y-mAbs Therapeutics
  • Class Antineoplastics; Immunotherapies; Iodine radioisotopes; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; Ionising radiation emitters; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma; Meningeal carcinomatosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Neuroblastoma
  • Phase II Ependymoma; Medulloblastoma; Peritoneal cancer; Soft tissue sarcoma
  • Suspended CNS cancer
  • No development reported Meningeal carcinomatosis; Solid tumours

Most Recent Events

  • 31 Dec 2024 Y-mAbs Therapeutics terminates its license for Omburtamab I-131 before December 2024
  • 30 Nov 2024 Suspended - Phase-I for CNS cancer (In adolescents, In children, In the elderly, In infants, In adults) in USA (Intrathecal)
  • 31 Oct 2023 Y-mAbs Therapeutics terminates a phase I trial in Peritoneal cancer (In adolescents, In adults, In children, In infants, In the elderly, Metastatic disease, Second-line therapy or greater) in USA (Intraperitoneal) due to corporate business decision (NCT01099644)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top